Trademarks and Trade Names All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners
Reported and plausible concerns Finally, Nausea, flushing, headache, fatigue, yawning, and appetite changes Consequently, Spontaneous erections and possible priapism For example, Generalized darkening and changes in freckles or existing moles Moreover, Uncertain long-term melanocyte and melanoma-related risk In addition, Unknown cardiovascular, endocrine, reproductive, and drug-interaction effects However, Contamination or dosing variability in unregulated products Current evidence does not prove that Melanotan II directly causes melanoma
After demonstrating that SYNCRIP enhances SIRT1 expression and attenuates ferroptosis, we investigated the molecular mechanisms underlying this regulation
Journal of the National Cancer Institute (2003) 11